Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

More Furious Than Ever: Escherichia coli-Acquired Co-resistance Toward Colistin and Carbapenems

More Furious Than Ever: Escherichia coli-Acquired Co-resistance Toward Colistin and Carbapenems More Furious Than Ever: Escherichia coli-Acquired Co-resistance Toward Colistin and Carbapenems TOTHE EDITOR—The emergence of plas- mid-mediated colistin resistance heralds the breach of the last group of antibiotics, polymyxins. In our previous reports, co- listin resistance has been reported in clin- ical isolates and mutations within the 2 component regularity systems resulting in the constitutive activation and subse- quent expression of lipopolysaccharide- modifying genes [1, 2]. Escherichia coli MK108 was isolated from a urine sample obtained from an inpatient at a university hospital in India in 2016. Bacterial iden- tification was performed by standard bio- chemical analysis and confirmed by 16S ribosomal RNA sequencing [1]. Suscept- ibility of E. coli MK108 was tested against antimicrobial agents according to the Clinical and Laboratory Standards Insti- tute broth microdilution procedure and interpretation criteria. Escherichia coli ATCC 25922 was used as reference strain. CORRESPONDENCE � CID 2016:63 (1 November) � 1267 isolates from India. It should be further noted that E. coli MK108 showed high re- sistance to carbapenems and colistin and intermediate resistance to tigecycline. Al- though the origin of this E. coli strain is not known, it is important to continuous- ly monitor the frequency of these genes in India. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Clinical Infectious Diseases Oxford University Press

More Furious Than Ever: Escherichia coli-Acquired Co-resistance Toward Colistin and Carbapenems

Download PDF
2 pages

Loading next page...
 
/lp/oxford-university-press/more-furious-than-ever-escherichia-coli-acquired-co-resistance-toward-TREUDkvPOL

References (5)

Publisher
Oxford University Press
Copyright
The Author 2016. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail journals.permissions@oup.com
ISSN
1058-4838
eISSN
1537-6591
DOI
10.1093/cid/ciw508
pmid
27470242
Publisher site
See Article on Publisher Site

Abstract

More Furious Than Ever: Escherichia coli-Acquired Co-resistance Toward Colistin and Carbapenems TOTHE EDITOR—The emergence of plas- mid-mediated colistin resistance heralds the breach of the last group of antibiotics, polymyxins. In our previous reports, co- listin resistance has been reported in clin- ical isolates and mutations within the 2 component regularity systems resulting in the constitutive activation and subse- quent expression of lipopolysaccharide- modifying genes [1, 2]. Escherichia coli MK108 was isolated from a urine sample obtained from an inpatient at a university hospital in India in 2016. Bacterial iden- tification was performed by standard bio- chemical analysis and confirmed by 16S ribosomal RNA sequencing [1]. Suscept- ibility of E. coli MK108 was tested against antimicrobial agents according to the Clinical and Laboratory Standards Insti- tute broth microdilution procedure and interpretation criteria. Escherichia coli ATCC 25922 was used as reference strain. CORRESPONDENCE � CID 2016:63 (1 November) � 1267 isolates from India. It should be further noted that E. coli MK108 showed high re- sistance to carbapenems and colistin and intermediate resistance to tigecycline. Al- though the origin of this E. coli strain is not known, it is important to continuous- ly monitor the frequency of these genes in India.

Journal

Clinical Infectious Diseases – Oxford University Press

Published: Nov 1, 2016

There are no references for this article.